While bladder cancer treatment can require removal of the bladder, new FDA-approved therapy offers bladder-saving approach Business AnnouncementUNIVERSITY OF CALIFORNIA – SAN DIEGO IMAGE: AMIRALI SALMASI, MD, IS A UROLOGIST AT UC SAN DIEGO HEALTH.CREDIT: UC SAN DIEGO HEALTH UC San Diego Health is the first health system in San Diego County to offer a...
Tag: <span>Bladder Cancer</span>
Post
Drug combo marks advance against bladder cancer
by Ernie Mundell A cancer drug duo more than doubled the survival of people battling the most common form of advanced bladder cancer, trial results show. Patients who took a combo of meds called EV+P—enfortumab vedotin and pembrolizumab (Keytruda)—had an average of 31.5 months survival, compared to just over 16 months for those on standard...
Post
Clinical trial: New dual therapy could revolutionize treatment of urothelial and bladder cancers
by Georgia Gowing, Macquarie University Dr. Alison Zhang. Credit: Macquarie UniversityAn international clinical trial of a treatment for advanced urothelial cancer has found a new dual therapy can nearly double patients’ life expectancy. The new immunotherapy is a combination of two drugs—enfortumab vedotin (EV) and pembrolizumab—delivered by infusion, and it is now being submitted to regulatory...
Post
Urine Test Predicts Future Bladder Cancer 12 Years Before Symptoms
Neil Osterweil A simple urine test for genetic mutations in urine-derived DNA can predict urothelial cancer up to 12 years before patients develop symptoms, an international team of researchers claims. The test, if validated in further studies, has the potential to serve as a cancer screening tool for individuals at elevated risk for bladder cancer...
Post
Simple noninvasive test may lead to breakthrough in early diagnosis of bladder cancer
ELSEVIER IMAGE: FRESH VOIDED URINE SAMPLES WERE COLLECTED INTO TUBES CONTAINING PRESERVATIVE BUFFER. TOTAL DNA WAS EXTRACTED FROM THE URINE SEDIMENTS AND UNDERWENT BISULFITE CONVERSION. SUBSEQUENTLY, LINEAR TARGET ENRICHMENT (LTE) AND QUANTITATIVE METHYLATION-SPECIFIC PCR (QMSP) WERE CONDUCTED TO DETERMINE THE LEVEL OF PENK METHYLATION ASSOCIATED WITH BLADDER CANCER. A POSITIVE RESULT INDICATES A HIGHER PROBABILITY...
Post
Exposure to Agent Orange linked to risk of bladder cancer
by Elana Gotkine Exposure to Agent Orange is associated with a small but significantly increased risk of bladder cancer among male Vietnam veterans, according to a study published online June 27 in JAMA Network Open. Steven B. Williams, M.D., from the University of Texas Medical Branch at Galveston, and colleagues examined the association between bladder cancer risk and...
Post
‘A piece of plastic with a 40-year-old drug in it’: J&J touts promising early data for bladder cancer treatment
Lei Lei WuNews Reporter In an early cut of data, Johnson & Johnson said Sunday afternoon that seven of eight bladder cancer patients who received its experimental bladder cancer treatment — a decades-old chemotherapy delivered in a device which its developers call “the pretzel” — saw their tumors go away. The Phase II study, known...
Post
Urine Test Predicts Future Bladder Cancer 12 Years Before Symptoms
Neil Osterweil March 13, 2023 A simple urine test for genetic mutations in urine-derived DNA can predict urothelial cancer up to 12 years before patients develop symptoms, an international team of researchers claims. The test, if validated in further studies, has the potential to serve as a cancer screening tool for individuals at elevated risk for bladder...
Post
Modified bladder cancer treatment shows promise in animal studies
by Texas Biomedical Research Institute BCG is a live attenuated vaccine used to protect against the development of tuberculosis disease, and is also used as the gold standard treatment for bladder cancer. BCG contains an array of surface lipids that are highly inflammatory (top row). The Texas Biomed team “delipidated” the BCG vaccine by removing...
Post
Older adults with advanced bladder cancer prioritize honest information about what to expect
by Rachel Sauer, CU Anschutz Medical Campus Credit: CC0 Public Domain The median age for receiving a bladder cancer diagnosis is 73, and a significant number of those living with the disease are in their 70s and 80s. A longstanding stereotype in cancer care is that older patients favor a more paternalistic style of care, one in which they...